| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Alissa R Segal | |
| Nuha El Sayed | |||
| P2860 | cites work | A caution regarding U-500 insulin by continuous subcutaneous infusion | Q44980659 |
| The effect of long-term use of U-500 insulin via continuous subcutaneous infusion on durability of glycemic control and weight in obese, insulin-resistant patients with type 2 diabetes | Q45893987 | ||
| Reduced risk of hypoglycemia with insulin degludec versus insulin glargine in patients with type 2 diabetes requiring high doses of basal insulin: a meta-analysis of 5 randomized begin trials | Q46129839 | ||
| Intensive conventional insulin therapy for type II diabetes. Metabolic effects during a 6-mo outpatient trial | Q46936072 | ||
| Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes | Q49174475 | ||
| Achievement of goals in U.S. diabetes care, 1999-2010. | Q51045064 | ||
| Glycemic control with continuous subcutaneous insulin infusion with use of U-500 insulin in a pregnant patient. | Q51127892 | ||
| Use of U-500 regular insulin by continuous subcutaneous insulin infusion in patients with type 2 diabetes and severe insulin resistance. | Q51181445 | ||
| Extreme insulin resistance: clinical management by external subcutaneous insulin infusion. | Q54145124 | ||
| Response to Comment on Sato et al. Improving type 2 diabetes through a distinct adrenergic signaling pathway involving mTORC2 that mediates glucose uptake in skeletal muscle. Diabetes 2014;63:4115-4129. | Q55070124 | ||
| Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes | Q84440683 | ||
| Assessment of a new insulin preparation for implanted pumps used in the treatment of type 1 diabetes | Q87686537 | ||
| Ligand-controlled assembly of hexamers, dihexamers, and linear multihexamer structures by the engineered acylated insulin degludec | Q27683621 | ||
| Comparison of insulin regimens in patients with non-insulin-dependent diabetes mellitus | Q34255525 | ||
| The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes | Q35085591 | ||
| A novel use of U-500 insulin for continuous subcutaneous insulin infusion in patients with insulin resistance: a case series | Q35198986 | ||
| Pharmacokinetics and pharmacodynamics of high-dose human regular U-500 insulin versus human regular U-100 insulin in healthy obese subjects | Q35563634 | ||
| A systems approach to reducing errors in insulin therapy in the inpatient setting | Q35835344 | ||
| Clinical use of U-500 regular insulin: review and meta-analysis | Q36051311 | ||
| The use of U-500 in patients with extreme insulin resistance | Q36108415 | ||
| Application of PK/PD modeling and simulation to dosing regimen optimization of high-dose human regular U-500 insulin. | Q36608993 | ||
| Clinical efficacy and patient satisfaction with U-500 insulin pump therapy in patients with type 2 diabetes | Q37056919 | ||
| Learning about new therapies: phase 3 clinical studies--and beyond | Q37106427 | ||
| Low-volume insulin degludec 200 units/ml once daily improves glycemic control similarly to insulin glargine with a low risk of hypoglycemia in insulin-naive patients with type 2 diabetes: a 26-week, randomized, controlled, multinational, treat-to-ta | Q37106509 | ||
| Use of concentrated insulin human regular (U-500) for patients with diabetes | Q37784645 | ||
| Insulin degludec: overview of a novel ultra long-acting basal insulin | Q38067424 | ||
| The use of U-500 regular insulin in the management of patients with obesity and insulin resistance | Q38089255 | ||
| Use of U-500 regular insulin via continuous subcutaneous insulin infusion: clinical practice experience | Q42938553 | ||
| A prospective trial of U500 insulin delivered by Omnipod in patients with type 2 diabetes mellitus and severe insulin resistance | Q43115619 | ||
| New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using basal and mealtime insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 1). | Q44485772 | ||
| A comparison of the steady-state pharmacokinetic and pharmacodynamic profiles of 100 and 200 U/mL formulations of ultra-long-acting insulin degludec | Q44599380 | ||
| Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes | Q44909481 | ||
| P433 | issue | 2 | |
| P304 | page(s) | 331-338 | |
| P577 | publication date | 2014-11-10 | |
| P1433 | published in | Journal of Diabetes Science and Technology | Q15755249 |
| P1476 | title | Are you ready for more insulin concentrations? | |
| P478 | volume | 9 |
| Q37054680 | Attributes Influencing Insulin Pen Preference Among Caregivers and Patients With Diabetes Who Require Greater Than 20 Units of Mealtime Insulin |
| Q40955457 | Challenges With Insulin in the Inpatient Setting |
| Q41866230 | Challenges in Delivering Smaller Doses of Insulin |
| Q26750438 | Concentrated insulins: the new basal insulins |
| Q39285855 | Higher concentration insulins: an overview of clinical considerations |
| Q38570757 | Management of Severe Insulin Resistance in Patients with Type 1 Diabetes |
| Q44372707 | Novel Concentrated Insulin Delivery Devices: Developments for Safe and Simple Dose Conversions |
| Q47322851 | Understanding concentrated insulins: a systematic review of randomized controlled trials. |
Search more.